SPYRE THERAPEUTICS, INC. (SYRE) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2025-12-31..
Gross margin
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2025-12-31 | (m) | $0.00 | (m) | (m) |
| 2024-12-31 | (m) | $0.00 | (m) | (m) |
| 2024-09-30 | (m) | $0.00 | (m) | (m) |
| 2024-06-30 | (m) | $0.00 | (m) | (m) |
| 2024-03-31 | (m) | $688.00K | (m) | (m) |
| 2023-12-31 | (m) | $886.00K | (m) | (m) |
| 2023-09-30 | (m) | $1.05M | (m) | (m) |
| 2023-06-30 | (m) | $1.23M | (m) | (m) |
| 2023-03-31 | (m) | $1.17M | (m) | (m) |
| 2022-12-31 | (m) | $2.33M | (m) | (m) |
| 2022-09-30 | (m) | $5.80M | (m) | (m) |
| 2022-06-30 | (m) | $7.03M | (m) | (m) |
| 2022-03-31 | (m) | $20.10M | (m) | (m) |
| 2021-12-31 | (m) | $18.74M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $0.00 | (m) | (m) |
| 2019-12-31 | (m) | $0.00 | (m) | (m) |
| 2019-09-30 | (m) | $0.00 | (m) | (m) |
| 2019-06-30 | (m) | $0.00 | (m) | (m) |
| 2019-03-31 | (m) | $2.38M | (m) | (m) |
| 2018-12-31 | (m) | $3.89M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $5.73M | (m) | (m) |
| 2017-12-31 | (m) | $5.21M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $4.63M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |